66,211 Shares in ALX Oncology Holdings Inc. (NASDAQ:ALXO) Bought by abrdn plc

abrdn plc bought a new position in ALX Oncology Holdings Inc. (NASDAQ:ALXO) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 66,211 shares of the company’s stock, valued at approximately $986,000. abrdn plc owned about 0.13% of ALX Oncology as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in ALX Oncology in the fourth quarter valued at approximately $28,000. SG Americas Securities LLC purchased a new position in ALX Oncology in the third quarter worth $48,000. Forefront Analytics LLC bought a new position in ALX Oncology in the third quarter valued at $66,000. China Universal Asset Management Co. Ltd. raised its position in ALX Oncology by 445.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,762 shares of the company’s stock valued at $86,000 after purchasing an additional 4,706 shares in the last quarter. Finally, J.P. Morgan Private Wealth Advisors LLC purchased a new position in shares of ALX Oncology in the 3rd quarter worth about $96,000. Hedge funds and other institutional investors own 97.97% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the company. Cantor Fitzgerald restated an “overweight” rating on shares of ALX Oncology in a research report on Friday, April 12th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of ALX Oncology in a report on Wednesday, April 10th. Finally, Stifel Nicolaus restated a “hold” rating and set a $14.00 price target (up from $10.00) on shares of ALX Oncology in a research report on Friday, March 8th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $18.83.

ALX Oncology Trading Up 0.4 %

Shares of ALXO opened at $16.93 on Tuesday. The firm has a fifty day simple moving average of $13.65 and a two-hundred day simple moving average of $12.36. ALX Oncology Holdings Inc. has a twelve month low of $3.94 and a twelve month high of $17.45. The stock has a market capitalization of $846.50 million, a P/E ratio of -4.51 and a beta of 1.58. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.05.

ALX Oncology (NASDAQ:ALXO) last posted its earnings results on Thursday, March 7th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.09). On average, research analysts anticipate that ALX Oncology Holdings Inc. will post -3.33 EPS for the current year.

Insider Activity

In related news, insider Jaume Pons sold 50,000 shares of ALX Oncology stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $14.20, for a total value of $710,000.00. Following the sale, the insider now owns 604,205 shares in the company, valued at $8,579,711. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other ALX Oncology news, insider Jaume Pons sold 50,000 shares of the firm’s stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $14.20, for a total value of $710,000.00. Following the completion of the sale, the insider now directly owns 604,205 shares in the company, valued at $8,579,711. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Jason Lettmann bought 4,400 shares of ALX Oncology stock in a transaction on Thursday, March 14th. The shares were purchased at an average price of $11.31 per share, for a total transaction of $49,764.00. Following the acquisition, the chief executive officer now directly owns 171,620 shares in the company, valued at approximately $1,941,022.20. The disclosure for this purchase can be found here. Insiders own 50.30% of the company’s stock.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.